Agile Therapeutics, Inc. (AGRX)
| Market Cap | 245.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -40.25M |
| Shares Out | 87.35M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $2.81 |
| Previous Close | $2.84 |
| Change ($) | -0.03 |
| Change (%) | -1.06% |
| Day's Open | 2.82 |
| Day's Range | 2.81 - 2.86 |
| Day's Volume | 714,058 |
| 52-Week Range | 1.58 - 4.40 |
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will ...
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morga...
Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA ...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)
PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an international, peer-reviewed, r...
PRINCETON, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Officer...
The drugmaker will soon give Twirla a twirl.
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q3 2020 Results - Earnings Call Transcript
Commercial Launch of Twirla® Expected by Year-End 2020
Live Conference Call and Webcast at 4:30 p.m. ET
PRINCETON, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and CEO Al Altomari will be virtually...
PRINCETON, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that Al Altomari, Chairman and Chi...
Company to Present Twirla® Commercial Plan
Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options
PRINCETON, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced the appointment of Paul Korner, MD,...
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q2 2020 Results - Earnings Call Transcript
PRINCETON, N.J., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Al Altomari, Chairman and Chief Executive Offic...
Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics (AGRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
PRINCETON, N.J., June 16, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that the Company will be added to the Russell 3000® ...
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q1 2020 Results - Earnings Call Transcript
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
Agile's shares are heating up ahead of the company's Q1 earnings report.
Agile Therapeutics: Billion Dollar Buy-Out Is On The Horizon
PRINCETON, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sha...
Agile Therapeutics (AGRX) closed at $1.86 in the latest trading session, marking no change from the prior day.
Investors need to pay close attention to Agile Therapeutics (AGRX) stock based on the movements in the options market lately.
The biotech stock is getting hit hard by the marketwide downturn today. Here's why.
Agile's stock can't seem to find a bottom, despite a major regulatory approval earlier this month.
Shares drop after the company releases the pricing details of a recently announced capital raise.
Agile Therapeutics (AGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is (AGRX) Outperforming Other Medical Stocks This Year?
PRINCETON, N.J., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 1...
PRINCETON, N.J., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its comm...
Twirla now has a green light from the FDA. And that could mean a green light for investors looking for a promising small-cap biotech stock.
Agile Therapeutics Inc. (NASDAQ: AGRX) shares took a dip on Tuesday after the company announced a key U.S.
Agile Could Reach $10/Share After Twirla Approval
Coronavirus is having a major impact across sectors.
Twirla® is a new non-daily, non-invasive contraceptive approved in the U.S.
The drugmaker is borrowing money to tide it over until it can hopefully achieve commercial success for its first product.
Bargain-seeking investors might want to look at these three stocks before venturing into the risky world of penny stocks.
Funding to Support the Company’s Commercialization Plans for Twirla ®
Short-Term Catalyst And Long-Term M&A Potential Make Agile Therapeutics An Attractive Potential Takeover Target
From a niche contraceptive to the world's top cancer treatment, the FDA has a number of interesting drugs its reviewing this month.
Agile Therapeutics' Market Potential, And Other News: The Good, Bad, And Ugly Of Biopharma
Agile: Recent AdCom Decisions Further Support Twirla Approval
Multibagger stocks can make most of the bull run, courtesy of strong fundamentals and businesses that can multiply in a short span of time.
PRINCETON, N.J., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the appointment of Kimberly Whelan as Vice President...
Agile: FDA Decision To Extend Twirla's PDUFA Date Provides Buying Opportunity
About AGRX
Agile Therapeutics, a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG2... [Read more...]
| Industry Drug Manufacturers-Specialty & Generic | IPO Date May 23, 2014 |
| CEO Alfred Altomari | Employees 15 |
| Stock Exchange NASDAQ | Ticker Symbol AGRX |
Analyst Forecasts
According to 5 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 8.25, which is an increase of 193.59% from the latest price.